All Dr Silke Schwengberg (Associate Director Cardiac Disease - Ncardia) articles
-
ArticleAn ethical shift in NHP research: iPSC-derived cardiomyocytes for safer pharmacology
As regulators move to phase out primate testing, NHP-derived iPSC cardiomyocytes are emerging as a scalable, ethical and scientifically robust alternative - offering drug developers a clear path to faster, more predictive, and more responsible innovation.